共 102 条
[1]
Miossec P(2012)Targeting IL-17 and TH17 cells in chronic inflammation Nat Rev Drug Discov 10 763-776
[2]
Kolls JK(2017)IL-17(+) gammadelta T cells as kick-starters of inflammation Nat Immunol 6 604-611
[3]
Papotto PH(2017)Interleukin 17 is a chief orchestrator of immunity Nat Immunol 6 612-621
[4]
Ribot JC(2014)The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing Nat Rev Immunol 9 585-600
[5]
Silva-Santos B(2009)Interleukin-17 as a drug target in human disease Trends Pharmacol Sci 2 95-103
[6]
Veldhoen M(2019)Ixekizumab: a review of its use for the Management of Moderate to severe plaque psoriasis Ann Pharmacother 3 276-284
[7]
Gaffen SL(2013)Effect of IL-17A blockade with secukinumab in autoimmune diseases Ann Rheum Dis 72 ii116-ii123
[8]
Jain R(2019)Short-term efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta-analysis of randomized controlled trials J Immunol Res 2019 2546161-123
[9]
Garg AV(2018)Interleukin-17 alters the biology of many cell types involved in the genesis of psoriasis, systemic inflammation and associated comorbidities Exp Dermatol 2 115-390
[10]
Cua DJ(2018)The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis Clin Rev Allergy Immunol 3 379-2259